Biotech Catalyst Daily
The morning catalyst calendar for investors and analysts allocating against FDA decisions, clinical readouts, and the approval cycle that moves the sector.
- PDUFA dates and advisory committee calendars across oncology, rare disease, and neuro.
- Phase II and III readouts with the endpoint context the press release leaves out.
- FDA complete response letters, accelerated approval conversions, and label-expansion moves.
- Licensing deals, M&A, and the Street’s reaction to the day’s biotech prints.
- Written for portfolio managers, analysts, and pharma BD teams — signal over hype.
Managing a book? Try Pro
Your watchlist, your therapeutic areas — plus readout prep 2 weeks before every binary event.
Ticker-filtered digest + CT.gov watchlist alerts + readout prep packs (14-21d out) + AdCom briefings (48h before) + FDA-decision alerts within 15 min. $49/month, 7 days free. Code FOUNDING_BIOTECH_50 locks 50% off for 12 months (first 100 subs).
What a morning briefing looks like
PDUFA decision expected Thursday for first-in-class rare-disease drug; Merck inks $1.2B oncology deal
Thursday’s Class I PDUFA on a first-in-class disease-modifying therapy is the binary event of the week — staff review signals approvability, but the confirmatory-trial post-market obligations will shape the commercial ramp. Separately, MRK announced a $1.2B licensing deal structured as $350M upfront with milestones weighted toward Phase 3 readouts.
Quick hits
- AdCom calendar: next week’s Oncologic Drugs Advisory Committee meeting on first-line NSCLC — staff review emphasizes OS benefit durability
- Phase 2 readout: positive OS signal but high discontinuation rate (22%) tempers the commercial read
- Accelerated approval conversion: FDA confirms three withdrawals for missed confirmatory-trial obligations
- JPM Healthcare Conference 2027 registration opens; agenda preview on late-stage oncology panel
Every weekday morning, 7:00 AM ET. 3-minute read. Signal over hype. Unsubscribe in one click.
Who subscribes
Buy-side biotech analysts at specialist + generalist funds.
Generalist PMs with biotech allocation who need catalyst calendar clarity.
BD & strategy leads at pharma tracking competitor pipelines.
Sell-side research associates drafting same-day reactions.
Biotech-focused VCs and crossover investors doing early-stage diligence.
IR & corporate development teams at biotechs who need the landscape read.
Editorial principles
- No tickers in the email subject line. We’re not a trading newsletter; we’re a briefing for professionals.
- No trading recommendations. We cover catalysts and mechanics; you allocate.
- Endpoint context always. Every clinical readout gets a plain-English frame — what the primary endpoint means, what the placebo prior looks like, where subgroup mining is likely.
- No sponsored coverage. We don’t take money from biotech companies to write about them.
- Human-edited every morning. AI-assisted drafting; human editing for accuracy and clinical nuance.
Recent Editions
- PDUFA watch: this quarter’s binary events across oncology and rare disease.
- FDA AdCom recaps — how the committee votes mapped to approvability reads.
- Accelerated approval conversions in 2026 and what endpoint slippage means for stocks.
- Deal tape — licensing terms, upfronts, and what buyers are signaling on valuation.
Also Available
- Deep Dives — longer-form analysis of catalyst mechanics and regulatory patterns
- RSS feed — read in your favorite reader
- Biotech Catalyst Pro — ticker-filtered digest, clinical-trial watchlist alerts, readout prep packs, AdCom briefings, FDA decision alerts (paid, $49/mo, 7-day trial)